BALL Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BALL Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $2.75B | Mar 1, 2018 |
| FY2017 | Sep 30, 2017 | $2.91B | Mar 1, 2018 |
| FY2017 | Jun 30, 2017 | $2.86B | Mar 1, 2018 |
| FY2017 | Mar 31, 2017 | $2.47B | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $2.52B | Mar 1, 2018 |
| FY2017 | Sep 30, 2016 | $2.75B | Mar 1, 2018 |
| FY2017 | Jun 30, 2016 | $2.03B | Mar 1, 2018 |
| FY2017 | Mar 31, 2016 | $1.76B | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $1.81B | Mar 2, 2017 |
| FY2016 | Sep 30, 2015 | $2.10B | Mar 2, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $480.00M | Feb 20, 2025 |
| FY2024 | Sep 30, 2024 | $545.00M | Feb 20, 2025 |
| FY2024 | Jun 30, 2024 | $489.00M | Feb 20, 2025 |
| FY2024 | Mar 31, 2024 | $477.00M | Feb 20, 2025 |
| FY2024 | Dec 31, 2023 | $483.00M | Feb 20, 2025 |
| FY2024 | Sep 30, 2023 | $487.00M | Feb 20, 2025 |
| FY2024 | Jun 30, 2023 | $453.00M | Feb 20, 2025 |
| FY2024 | Mar 31, 2023 | $441.00M | Feb 20, 2025 |
| FY2019 | Dec 31, 2019 | $437.00M | Feb 19, 2020 |
| FY2019 | Sep 30, 2019 | $468.00M | Feb 19, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $444.00M | Feb 22, 2012 |
| FY2010 | Dec 31, 2010 | $468.00M | Feb 28, 2011 |
| FY2010 | Dec 31, 2009 | $387.90M | Feb 28, 2011 |
| FY2010 | Dec 31, 2008 | $319.50M | Feb 28, 2011 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.27B | Feb 20, 2024 |
| FY2023 | Dec 31, 2022 | $1.21B | Feb 20, 2024 |
| FY2023 | Dec 31, 2021 | $1.29B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $1.00B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $932.00M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $935.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $802.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $463.00M | Feb 22, 2019 |
| FY2016 | Sep 30, 2016 | $132.00M | Mar 2, 2017 |
| FY2016 | Jun 30, 2016 | $279.00M | Mar 2, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $55.00M | Feb 20, 2024 |
| FY2023 | Dec 31, 2022 | $55.00M | Feb 20, 2024 |
| FY2023 | Dec 31, 2021 | $56.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $47.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $44.00M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $32.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $27.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $28.00M | Feb 22, 2019 |
| FY2017 | Dec 31, 2015 | $26.00M | Mar 1, 2018 |
| FY2016 | Dec 31, 2014 | $27.00M | Mar 2, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $566.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $647.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $532.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $555.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $593.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $525.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $417.00M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $478.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $514.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $512.00M | Feb 22, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.26B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $115.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.86B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $301.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.76B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $1.43B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $1.55B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $1.57B | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $1.48B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $193.00M | Feb 22, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $474.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $484.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.05B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.65B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.73B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $1.11B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $598.00M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $816.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $556.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $606.00M | Feb 22, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.52B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $17.63B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $19.30B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $19.91B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $19.71B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $18.25B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $17.36B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $16.55B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $17.17B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $16.17B | Mar 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.10B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $11.70B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $15.47B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $16.38B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $16.03B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $14.92B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $14.34B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $12.99B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $13.12B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $12.63B | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.42B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $5.86B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $3.77B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $3.46B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $3.63B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $3.28B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $2.95B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $3.46B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $3.94B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $3.44B | Mar 1, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.38B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $4.17B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $4.25B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $4.20B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $4.38B | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $4.48B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $4.42B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $4.48B | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $4.93B | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $5.10B | Feb 22, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.22B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $11.53B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $7.76B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $7.31B | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $6.84B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $6.19B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $5.80B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $5.34B | Feb 19, 2020 |
| FY2018 | Jan 2, 2018 | $5.02B | Feb 22, 2019 |
| FY2018 | Dec 31, 2017 | $4.99B | Feb 22, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.21B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $885.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $695.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $548.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $563.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $1.37B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $1.80B | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $721.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $448.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $597.00M | Feb 22, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $7.79B | Feb 19, 2020 |
| FY2019 | Dec 31, 2018 | $6.52B | Feb 19, 2020 |
| FY2018 | Dec 31, 2017 | $6.63B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $7.39B | Mar 1, 2018 |
| FY2016 | Dec 31, 2015 | $5.03B | Mar 2, 2017 |
| FY2015 | Dec 31, 2014 | $3.05B | Feb 16, 2016 |
| FY2014 | Dec 31, 2013 | $3.55B | Feb 20, 2015 |
| FY2013 | Dec 31, 2012 | $3.19B | Feb 24, 2014 |
| FY2012 | Dec 31, 2011 | $2.76B | Feb 22, 2013 |
| FY2011 | Dec 31, 2010 | $2.74B | Feb 22, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 19, 2026 |
| FY2024 | Dec 31, 2024 | 0 | Feb 20, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Feb 20, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Feb 20, 2025 |
| FY2024 | Mar 31, 2024 | 11 | Feb 20, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Feb 20, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 20, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Feb 20, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Feb 20, 2025 |
| FY2024 | Dec 31, 2022 | 2 | Feb 20, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 19, 2026 |
| FY2024 | Dec 31, 2024 | 0 | Feb 20, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Feb 20, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Feb 20, 2025 |
| FY2024 | Mar 31, 2024 | 11 | Feb 20, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Feb 20, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 20, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Feb 20, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Feb 20, 2025 |
| FY2024 | Dec 31, 2022 | 2 | Feb 20, 2025 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $220.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $244.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $252.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $254.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $229.00M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $198.00M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $182.00M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $137.00M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $129.00M | Feb 19, 2020 |
| FY2018 | Dec 31, 2016 | $83.00M | Feb 22, 2019 |